US Stock MarketDetailed Quotes
KZIA Kazia Therapeutics
- 0.403
- -0.003-0.84%
Close Oct 14 16:00 ET
- 0.399
- -0.004-0.94%
Pre 08:44 ET
13.40MMarket Cap-1073P/E (TTM)
0.415High0.399Low147.32KVolume0.406Open0.406Pre Close59.35KTurnover0.47%Turnover RatioLossP/E (Static)33.29MShares1.58052wk High3.80P/B12.76MFloat Cap0.18752wk Low--Dividend TTM31.70MShs Float15.850Historical High--Div YieldTTM4.01%Amplitude0.187Historical Low0.402Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Kazia Therapeutics Stock Forum
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients With Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting
Treatment with 45mg paxalisib and radiotherapy demonstrated 67% partial response (PR)
Over two-thirds of the patients at maximum tolerated dose (MTD) achieved intracrani...
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
SYDNEY, Sept. 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15thBiennial Ovarian Cancer Research Symposium, co-presented by American ...
+200% run within couple weeks. 😉
Placed as a placeholder.
Let's see......
hmmmmmm
still going down
No comment yet